BACKGROUND: Adjunctive hyperbaric oxygen therapy is a safe and effective modality with which to increase tissue oxygenation and aid in healing of difficult wounds. The majority of the literature surrounding hyperbaric oxygen therapy supports its use in chronic wounds, but its use in acute wounds, flaps, and grafts is less well supported. METHODS: The authors reviewed the Ovid, PubMed, and Cochrane Library databases, and selected studies, level III and above, using hyperbaric oxygen therapy in the treatment of complicated acute wounds, flaps, and grafts. RESULTS: A total of eight studies were found to meet criteria for evaluation of adjunctive hyperbaric oxygen therapy in the treatment of complicated acute wounds, flaps, and grafts. CONCLUSIONS: When combined with standard wound management principles, hyperbaric oxygen therapy can augment healing in complicated acute wounds. However, it is not indicated in normal wound management. Further investigation is required before it can be recommended as a mainstay in adjuvant wound therapy. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.
BACKGROUND: Adjunctive hyperbaric oxygen therapy is a safe and effective modality with which to increase tissue oxygenation and aid in healing of difficult wounds. The majority of the literature surrounding hyperbaric oxygen therapy supports its use in chronic wounds, but its use in acute wounds, flaps, and grafts is less well supported. METHODS: The authors reviewed the Ovid, PubMed, and Cochrane Library databases, and selected studies, level III and above, using hyperbaric oxygen therapy in the treatment of complicated acute wounds, flaps, and grafts. RESULTS: A total of eight studies were found to meet criteria for evaluation of adjunctive hyperbaric oxygen therapy in the treatment of complicated acute wounds, flaps, and grafts. CONCLUSIONS: When combined with standard wound management principles, hyperbaric oxygen therapy can augment healing in complicated acute wounds. However, it is not indicated in normal wound management. Further investigation is required before it can be recommended as a mainstay in adjuvant wound therapy. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, II.
Authors: Ana Carolina A V Kayano; João Conrado K Dos-Santos; Marcele F Bastos; Leonardo J Carvalho; Júlio Aliberti; Fabio T M Costa Journal: Infect Immun Date: 2016-03-24 Impact factor: 3.441
Authors: Ian L Millar; Rosemary A McGinnes; Owen Williamson; Folke Lind; Karl-Åke Jansson; Michal Hajek; David Smart; Tiago Fernandes; Russell Miller; Paul Myles; Peter Cameron Journal: BMJ Open Date: 2015-06-11 Impact factor: 2.692
Authors: G S A Boersema; Z Wu; L F Kroese; S Vennix; Y M Bastiaansen-Jenniskens; J W van Neck; K H Lam; G J Kleinrensink; J Jeekel; J F Lange Journal: Int J Colorectal Dis Date: 2016-04-04 Impact factor: 2.571